CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource®, LLC (PER®), a worldwide leading resource for continuing medical education, has released the agenda for the 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®. The conference will take place Nov. 6-8 at the New York Marriott Marquis in New York City.
“This fall we look forward to having oncology professionals from around the world attend our three-day marquee oncology CME conference in New York City,” said Phil Talamo, president of PER®. “Oncology data is evolving at an unprecedented rate, and the opportunities to share clinical experience across tumors, particularly with novel targeted agents and immunotherapies, are needed for the cancer team to provide state-of-the-art treatments. This year’s meeting will focus on the cutting edge of medicine, and how new treatments are trailblazing contemporary oncology care.”
Each year, the Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® brings together more than 1,000 health care professionals for three days to network with the top minds in oncology. At this year’s meeting, activity co-chairs — Drs. Adam M. Brufsky, Benjamin P. Levy and William K. Oh — will be joined by 100 internationally world-renowned experts who will provide attendees with expert insights on the latest developments in cancer therapeutics, offering an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer.
Additionally, the PER® Educator of the Year award, which highlights the accomplishments of oncology leaders and honors their contributions and efforts to propel the field of medical oncology through innovative and collaborative education will also be presented at this year’s conference.
For more information and to view the agenda or register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates, Inc., family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
